ESR1 and breast carcinoma: It would be interesting to analyze the effect of DEX at low and high doses in ER-positive, progesterone receptor (PR)-positive, human epidermal growth factor receptor 2 (HER2)-positive breast cancer cells, and in TNBC (Figure 2).